Using non-viral S/MAR plasmid vectors to develop prophylactic gene therapy for Birt-Hogg-Dubé Syndrome
Dr Richard Harbottle leads one of the Myrovlytis Trust gene therapy projects to develop a non-viral vector therapy for BHD. Building from their previous work, the Harbottle group are developing non-viral vectors which contain the Folliculin gene as a potential therapy for BHD syndrome. The goal is to deliver these vector to the kidney, skin, or lung cells of BHD patients to overcome the symptoms caused by the mutated Folliculin gene.
Dr Harbottle is head of the Gene Therapy Research Group at Imperial College and Research Fellow at the National Heart and Lung Institute.
Find out more about Dr Harbottle and his lab:
- watch an interview here
- read the written interview with Dr Suet-Ping Wong, a post-doctoral researcher in Dr Harbottle’s team
- read his Lab profile on the BHD Research Blog
- read the publications arising from this grant.
If you would like to support this project, please donate here.